Published in Antivir Ther on January 01, 2009
Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis (2012) 1.41
Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study. J Acquir Immune Defic Syndr (2014) 0.85
Comparison of two methodologies for CD4⁺ T lymphocytes relative counting on immune monitoring of patients with human immunodeficiency virus. ScientificWorldJournal (2012) 0.78
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol (2006) 5.25
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 4.43
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol (2009) 4.38
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol (2003) 4.15
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol (2004) 3.99
Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS (2006) 3.82
Clinical practice. Infective endocarditis. N Engl J Med (2013) 3.67
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis (2009) 3.28
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol (2005) 3.18
Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A (2010) 3.05
Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA (2007) 3.03
Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA (2012) 3.01
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer (2004) 2.98
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol (2006) 2.82
Effectiveness of co-trimoxazole to prevent Plasmodium falciparum malaria in HIV-positive pregnant women in sub-Saharan Africa: an open-label, randomized controlled trial. Clin Infect Dis (2013) 2.80
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol (2013) 2.78
Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS (2008) 2.74
Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis (2005) 2.67
Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One (2008) 2.62
Transparent development of the WHO rapid advice guidelines. PLoS Med (2007) 2.57
Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis (2004) 2.56
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat (2010) 2.50
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
Severe falciparum malaria in Gabonese children: clinical and laboratory features. Malar J (2005) 2.35
Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol (2014) 2.24
Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? AIDS (2011) 2.23
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med (2010) 2.17
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock (2002) 2.09
Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med (2004) 2.08
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog (2009) 2.06
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology (2014) 2.05
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One (2010) 2.05
The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. AIDS (2014) 2.04
Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis (2005) 2.03
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (2002) 2.03
Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol (2012) 2.02
Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis (2006) 2.02
Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol (2009) 1.98
Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis (2012) 1.97
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS (2003) 1.97
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis (2013) 1.95
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS (2010) 1.93
HIV infection in older patients in the HAART era. J Antimicrob Chemother (2005) 1.90
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Observation plans in longitudinal studies with time-varying treatments. Stat Methods Med Res (2008) 1.89
Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis (2011) 1.87
WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis (2007) 1.85
Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther (2007) 1.83
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. Arch Intern Med (2012) 1.77
Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol (2005) 1.77
Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS (2009) 1.74
Prevalence of Plasmodium falciparum infection in pregnant women in Gabon. Malar J (2003) 1.70
Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis (2003) 1.69
Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr (2007) 1.68
The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther (2007) 1.68
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis (2011) 1.68
Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS (2004) 1.67
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. AIDS (2010) 1.65
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol (2006) 1.63
Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma (2013) 1.62
Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up. AIDS (2009) 1.62
CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis (2013) 1.60
Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother (2004) 1.59
Increased prevalence of intestinal helminth infection during pregnancy in a Sub-Saharan African community. Wien Klin Wochenschr (2007) 1.58